KalVista Pharmaceuticals (NASDAQ:KALV) Price Target Lowered to $28.00 at Citizens Jmp

KalVista Pharmaceuticals (NASDAQ:KALV) had its target price trimmed by Citizens Jmp from $29.00 to $28.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The brokerage currently has a market outperform rating on the specialty pharmaceutical company’s stock.

A number of other research analysts have also weighed in on KALV. Citigroup reaffirmed a “market outperform” rating on shares of KalVista Pharmaceuticals in a research report on Tuesday. Needham & Company LLC reissued a “buy” rating and issued a $28.00 target price on shares of KalVista Pharmaceuticals in a research note on Friday, September 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research report on Wednesday, October 8th. Finally, JMP Securities upped their price target on shares of KalVista Pharmaceuticals from $27.00 to $28.00 and gave the stock a “market outperform” rating in a research note on Friday, September 12th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, KalVista Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $26.63.

KalVista Pharmaceuticals Price Performance

NASDAQ:KALV opened at $11.47 on Tuesday. The firm has a market capitalization of $579.50 million, a P/E ratio of -2.91 and a beta of -0.04. KalVista Pharmaceuticals has a one year low of $7.30 and a one year high of $17.28. The company’s 50-day simple moving average is $12.27 and its 200 day simple moving average is $12.81.

KalVista Pharmaceuticals (NASDAQ:KALV) last announced its earnings results on Monday, November 10th. The specialty pharmaceutical company reported ($0.92) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.96) by $0.04. The business had revenue of $13.69 million for the quarter, compared to the consensus estimate of $6.03 million. On average, equities research analysts expect that KalVista Pharmaceuticals will post -3.56 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Benjamin L. Palleiko sold 10,940 shares of KalVista Pharmaceuticals stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $13.22, for a total value of $144,626.80. Following the completion of the sale, the chief executive officer owned 386,858 shares of the company’s stock, valued at $5,114,262.76. The trade was a 2.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Paul K. Audhya sold 2,942 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.22, for a total value of $38,893.24. Following the completion of the transaction, the insider directly owned 119,841 shares in the company, valued at approximately $1,584,298.02. This represents a 2.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 26,856 shares of company stock worth $374,910. Company insiders own 4.30% of the company’s stock.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in KalVista Pharmaceuticals by 3.7% during the third quarter. Vanguard Group Inc. now owns 2,501,119 shares of the specialty pharmaceutical company’s stock valued at $30,464,000 after buying an additional 88,720 shares during the last quarter. Woodline Partners LP grew its position in shares of KalVista Pharmaceuticals by 25.5% during the 1st quarter. Woodline Partners LP now owns 1,617,469 shares of the specialty pharmaceutical company’s stock valued at $18,666,000 after acquiring an additional 329,068 shares during the period. Emerald Advisers LLC increased its stake in shares of KalVista Pharmaceuticals by 30.2% in the 3rd quarter. Emerald Advisers LLC now owns 1,351,254 shares of the specialty pharmaceutical company’s stock worth $16,458,000 after purchasing an additional 313,205 shares in the last quarter. Ameriprise Financial Inc. raised its holdings in KalVista Pharmaceuticals by 2,258.6% in the 2nd quarter. Ameriprise Financial Inc. now owns 945,125 shares of the specialty pharmaceutical company’s stock worth $10,685,000 after purchasing an additional 905,053 shares during the period. Finally, Geode Capital Management LLC raised its holdings in KalVista Pharmaceuticals by 2.8% in the 2nd quarter. Geode Capital Management LLC now owns 941,212 shares of the specialty pharmaceutical company’s stock worth $10,642,000 after purchasing an additional 25,971 shares during the period.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).